The Sonic hedgehog pathway inhibitor GDC0449 induces autophagic death in human Medulloblastoma Daoy cells

References

• Ciobanu-Caraus O, Czech T, Peyrl A, et al. The Site of Origin of Medulloblastoma: Surgical Observations Correlated to Molecular Groups. Cancers (Basel). 2023;15(19):4877. doi: 10.3390/cancers15194877
   PubMed Web of Science ®Google Scholar
• Cavalli Florence MG, Marc R, Ladislav R, et al. Intertumoral heterogeneity within Medulloblastoma subgroups. Cancer Cell. 2017;31(6):737–754.e6. doi: 10.1016/j.ccell.2017.05.005
   PubMed Web of Science ®Google Scholar
• Juraschka K, Taylor Michael D, et al. Medulloblastoma in the age of molecular subgroups: a review. Journal of Neurosurgery Pediatrics. 2019;24(4):353–363. doi: 10.3171/2019.5.PEDS18381
   PubMed Web of Science ®Google Scholar
• Moussalem C, Ftouni L, Mrad ZA, et al. Pediatric posterior fossa tumors outcomes: experience in a tertiary care center in the Middle East. Clinical Neurology and Neurosurgery. 2020;197(suppl_4):106170. doi: 10.1016/j.clineuro.2020.106170
   PubMedGoogle Scholar
• Gendreau Julian L, Shishir G, Giles Tyler X, et al. A retrospective analysis of the Demographics, treatment, and survival outcomes of patients with desmoplastic nodular Medulloblastoma using the surveillance, epidemiology, and end results (SEER) database.[J]. Cureus. 2020;12, e9042. doi: 10.7759/cureus.9042
   PubMed Web of Science ®Google Scholar
• Bunchoo P, Nongnuch S, Pacharapan S, et al. Pediatric primary central nervous system tumors registry in Thailand under National Health Security Office schemes. Journal of Neuro-Oncology. 2020;149(1):141–151. doi: 10.1007/s11060-020-03582-w
   PubMed Web of Science ®Google Scholar
• White Christine L, Samantha N JW, Daniel P, et al. A sexually dimorphic role for STAT3 in Sonic hedgehog Medulloblastoma. Cancers (Basel). 2019;11(11):1702. doi: 10.3390/cancers11111702
   PubMed Web of Science ®Google Scholar
• Northcott PA, Dubuc AM, Pfster S, Taylor MD. Molecular subgroups of medulloblastoma. Expert Review of Neurotherapeutics. 2012;12(7), 871–884. doi: 10.1586/ern.12.66
   PubMed Web of Science ®Google Scholar
• Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. Journal of Clinical Oncology. 2011;29(11):1408–1414. doi: 10.1200/JCO.2009.27.4324
   PubMed Web of Science ®Google Scholar
• Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica Communications. 2012;123(4):465–472. doi: 10.1007/s00401-011-0922-z
   Google Scholar
• PA N, GW R, CP K, et al. Medulloblastoma.[J]. Nature Reviews Disease Primers. 2019;5(1):12.
   PubMedGoogle Scholar
• Robinson Giles W, Rudneva Vasilisa A, Ivo B, et al. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncology. 2018;19(6):768–784. doi: 10.1016/S1470-2045(18)30204-3
   PubMed Web of Science ®Google Scholar
• Louis David N, Arie P, Pieter W, et al. The 2021 WHO classification of tumors of the central nervous System: a summary. Neuro-Oncology. 2021;23(8):1231–1251. doi: 10.1093/neuonc/noab106
   PubMed Web of Science ®Google Scholar
• Kuo-Shyang J, Chi-Juei J, Wen-Juei J, et al. Sonic hedgehog pathway inhibitor mitigates mouse hepatocellular carcinoma. American Journal of Surgery. 2015;210(3):554–560. doi: 10.1016/j.amjsurg.2015.03.001
   PubMed Web of Science ®Google Scholar
• Akshay P, Saurabh S, Vaibhav M, et al. Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling. Journal of Drug Targeting. 2012;20(9):770–782. doi: 10.3109/1061186X.2012.719900
   PubMed Web of Science ®Google Scholar
• Shih-Chiang K, Yao-Chou L. Giant basal cell carcinoma of the axilla: 8-year follow-up of a case treated with excision, Vismodegib, and Radiotherapy. Journal of Drugs in Dermatology. 2022;21(5):531–533. doi: 10.36849/JDD.6583
   PubMed Web of Science ®Google Scholar
• Liu Y, Liang Y, Fan L, et al. MiR-450a-5p strengthens the drug sensitivity of gefitinib in glioma chemotherapy via regulating autophagy by targeting EGFR.Oncogene. Oncogene. 2020;39(39):6190–6202. doi: 10.1038/s41388-020-01422-9
   PubMed Web of Science ®Google Scholar
• Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. Journal of Clinical Oncology. 2011;29(11):1408–1414. doi: 10.1200/JCO.2009.27.4324
   PubMed Web of Science ®Google Scholar
• Kijima N, Kanemura Y. Molecular classification of Medulloblastoma. Neurologia Medico-Chirurgica. 2016;56(11), 687–697. doi: 10.2176/nmc.ra.2016-0016
   PubMed Web of Science ®Google Scholar
• Cotter JA, Hawkins C. Medulloblastoma: medulloblastoma: WHO 2021 and beyond. Pediatric and Developmental Pathology. 2022;25(1):23–33. doi: 10.1177/10935266211018931
   PubMed Web of Science ®Google Scholar
• Kwang-Youn K, Kwang-Il P, Sang-Hun K, et al. Inhibition of autophagy promotes salinomycin-induced apoptosis via reactive oxygen species-mediated PI3K/AKT/mTOR and ERK/p38 MAPK-Dependent Signaling in human prostate Cancer cells. International journal of Molecular Sciences. 2017;18(5):1088. doi: 10.3390/ijms18051088
   PubMed Web of Science ®Google Scholar
• Chien-Ju L, Ta-Liang C, Yuan-Yun T, et al. Honokiol induces autophagic cell death in malignant glioma through reactive oxygen species-mediated regulation of the p53/PI3K/Akt/mTOR signaling pathway. Toxicology and Applied Pharmacology. 2016;304:59–69. doi: 10.1016/j.taap.2016.05.018
   PubMed Web of Science ®Google Scholar
• Poh-Shiow Y, Weu W, Ya-An C, et al. Honokiol induces autophagy of neuroblastoma cells through activating the PI3K/Akt/mTOR and endoplasmic reticular stress/ERK1/2 signaling pathways and suppressing cell migration. Cancer Letters. 2016;370(1):66–77. doi: 10.1016/j.canlet.2015.08.030
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. The New England Journal of Medicine. 2009;361(12):1173–1178. doi: 10.1056/NEJMoa0902903
   PubMed Web of Science ®Google Scholar
• Rudin Charles M. Vismodegib.[J]. Clinical Cancer Research. 2012;18(12):3218–3222. doi: 10.1158/1078-0432.CCR-12-0568
   PubMed Web of Science ®Google Scholar
• Aleksandar S, Hoff Daniel V. Hedgehog pathway inhibition. Cell. 2016;164(5):831. doi: 10.1016/j.cell.2016.02.021
   PubMed Web of Science ®Google Scholar
• Stephanie H, Patrick B, Ömer G, et al. Radiation sensitization of basal cell and head and neck squamous cell carcinoma by the hedgehog pathway inhibitor Vismodegib. International Journal of Molecular Sciences. 2018;19(9):2485. doi: 10.3390/ijms19092485
   PubMed Web of Science ®Google Scholar
• Masaru K. Genomic testing, tumor microenvironment and targeted therapy of hedgehog-related human cancers. Clinical Science. 2019;133(8):953–970. doi: 10.1042/CS20180845
   Web of Science ®Google Scholar
• Migden Michael R, Anne Lynn S C, Luc D, et al. Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treatment Reviews. 2018;64:1–10. doi: 10.1016/j.ctrv.2017.12.009
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Iwakuma T. Regulators of oncogenic mutant TP53 gain of function. Cancers (Basel). 2018;11(1):4. doi: 10.3390/cancers11010004
   PubMed Web of Science ®Google Scholar
• Lee C-L, Jordan MB, David GK. Role of p53 in regulating tissue response to radiation by mechanisms independent of apoptosis. Translational Cancer Research. 2013;2:412.
   PubMed Web of Science ®Google Scholar
• Levine B, Kroemer G. Biological functions of autophagy genes: a disease perspective - ScienceDirect. Cell. 2019;176(1–2):11–42. doi: 10.1016/j.cell.2018.09.048
   PubMed Web of Science ®Google Scholar
• Shikha Satendra S, Somya V, Amelia Yi-Qian C, et al. Dual role of autophagy in hallmarks of cancer. Oncogene. 2018;37(9):1142–1158. doi: 10.1038/s41388-017-0046-6
   PubMed Web of Science ®Google Scholar
• Jean M Mulcahy L, Towers Christina G, Andrew T. Targeting autophagy in cancer. Nature Reviews Cancer. 2017;17(9):528–542. doi: 10.1038/nrc.2017.53
   PubMed Web of Science ®Google Scholar
• Amaravadi Ravi K, Kimmelman Alec C, Jayanta D. Targeting autophagy in Cancer: recent advances and future directions. Cancer Discovery. 2019;9(9):1167–1181. doi: 10.1158/2159-8290.CD-19-0292
   PubMed Web of Science ®Google Scholar
• Qishan T, Guanwu L, Xiaoning W, et al. Resveratrol-induced apoptosis is enhanced by inhibition of autophagy in esophageal squamous cell carcinoma. Cancer Letter. 2013;336(2):325–337. doi: 10.1016/j.canlet.2013.03.023
   PubMed Web of Science ®Google Scholar
• Maurizio S. Crosstalk of autophagy and apoptosis. Cells. 2022;11(9):1479. doi: 10.3390/cells11091479
   PubMed Web of Science ®Google Scholar
• D’Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biology International. 2019;43(6):582–592. doi: 10.1002/cbin.11137
   PubMed Web of Science ®Google Scholar
• Nataliya Z, Vijay R, Marc R, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. Journal of Clinical Oncology. 2013;31(23):2927–2935. doi: 10.1200/JCO.2012.48.5052
   PubMed Web of Science ®Google Scholar
• Rechberger JS, Toll SA, Vanbilloen WJF, et al. Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment. Diagnostics (Basel). 2023;13(14):2398. doi: 10.3390/diagnostics13142398
   PubMedGoogle Scholar
• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous System: A summary. Journal of Neuro-Oncology. 2021;23(8):1231–1251. doi: 10.1093/neuonc/noab106
   Google Scholar
• Ahmed Swalih P, Castresana Javier S, Shahi Mehdi H. Role of circular RNA in brain tumor development. Cells. 2022;11(14):2130. doi: 10.3390/cells11142130
   PubMed Web of Science ®Google Scholar
• Ceccarelli Manuela DG, Laura M, Micheli L, et al. Tumor growth in the high frequency Medulloblastoma mouse model Ptch1+/−/Tis21KO has a specific activation signature of the PI3K/AKT/mTOR Pathway and is Counteracted by the PI3K inhibitor MEN1611. Frontiers in Oncology. 2021;11:692053. doi: 10.3389/fonc.2021.692053
   PubMed Web of Science ®Google Scholar
• Ingeborg H, Vincent Emma E, Tavaré Jeremy M. Akt signalling in health and disease. Cell Signal. 2011;23(10):1515–1527. doi: 10.1016/j.cellsig.2011.05.004
   PubMed Web of Science ®Google Scholar
• Maysa M A-K, Alex Hodge K, Christos H, et al. AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers. NPJ Precision Oncology. 2023;7(1):18. doi: 10.1038/s41698-023-00360-5
   PubMed Web of Science ®Google Scholar
• Joan B, Mien-Chie H, Mills Gordon B. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007;12(2):104–107. doi: 10.1016/j.ccr.2007.07.014
   PubMed Web of Science ®Google Scholar